Smart treatment switch: new approach personalizes breast cancer care before surgery
NCT ID NCT07393425
Summary
This study is testing two different drug combination strategies given before surgery for people with HER2-positive breast cancer. Participants first receive one drug combination, and if imaging shows the tumor isn't shrinking enough, they switch to a different combination. The goal is to shrink tumors as much as possible before surgery to improve long-term outcomes. The study is recruiting 50 women with stage II-III HER2-positive breast cancer who haven't had prior cancer treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2+ BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Jiaotong University School of Medicine affiliated Ruijin Hospital
RECRUITINGShanghai, Shanghai Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.